Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules

被引:170
作者
Nabors, GS
Braun, PA
Herrmann, DJ
Heise, ML
Pyle, DJ
Gravenstein, S
Schilling, M
Ferguson, LM
Hollingshead, SK
Briles, DE
Becker, RS
机构
[1] Aventis Pasteur, Swiftwater, PA 18370 USA
[2] Eastern Virginia Med Sch, Norfolk, VA 23507 USA
[3] Univ Alabama, Birmingham, AL 35294 USA
关键词
PspA; Streptococcus; pneumococcus;
D O I
10.1016/S0264-410X(99)00530-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pneumococcal surface protein A (PspA) is a highly variable protein found on all strains of pneumococci. To be successful, a PspA-based vaccine for S. pneumoniae must induce antibodies that are broadly cross-reactive. To address whether cross-reactive antibodies could be induced in man, we evaluated serum from adults immunized with recombinant clade 2 PspA from strain Rx1. Immunization with 5-125 mu g rPspA lead to a significant increase in circulating anti-PspA antibodies, as well as antibodies reactive to heterologous rPspA molecules. Increased binding of post-immune sera to 37 pneumococcal strains expressing a variety of PspA and capsule types was observed, Versus pre-immune sera. The extent of cross-clade reactivity of human anti-rPspA followed roughly the amount of sequence homology to the non-clade 2 antigens. It is hypothesized that priming of humans by natural exposure to S. pneumoniae contributes to the breadth of the cross-reactivity of antibody to PspA. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1743 / 1754
页数:12
相关论文
共 29 条
[1]   STREPTOCOCCUS-PNEUMONIAE - VIRULENCE FACTORS, PATHOGENESIS, AND VACCINES [J].
ALONSODEVELASCO, E ;
VERHEUL, AFM ;
VERHOEF, J ;
SNIPPE, H .
MICROBIOLOGICAL REVIEWS, 1995, 59 (04) :591-&
[2]  
[Anonymous], 1997, MMWR-MORBID MORTAL W, V46, P1
[3]  
Becker RS, 1997, VACCINES, P39
[4]  
BLACK SB, 1998, 38 INT C ANT AG CHEM
[5]   10-YEAR REVIEW OF OTITIS-MEDIA PATHOGENS [J].
BLUESTONE, CD ;
STEPHENSON, JS ;
MARTIN, LM .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1992, 11 (08) :S7-S11
[6]   Systemic and mucosal protective immunity to pneumococcal surface protein A [J].
Briles, DE ;
Tart, RC ;
Wu, HY ;
Ralph, BA ;
Russell, MW ;
McDaniel, LS .
MICROBIAL PATHOGENESIS AND IMMUNE RESPONSE II, 1996, 797 :118-126
[7]   PspA and PspC: Their potential for use as pneumococcal vaccines [J].
Briles, DE ;
Hollingshead, SK ;
Swiatlo, E ;
Brooks-Walter, A ;
Szalai, A ;
Virolainen, A ;
McDaniel, LS ;
Benton, KA ;
White, P ;
Prellner, K ;
Hermansson, A ;
Aerts, PC ;
Van Dijk, H ;
Crain, MJ .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1997, 3 (04) :401-408
[8]   PspA, a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in mice [J].
Briles, DE ;
King, JD ;
Gray, MA ;
McDaniel, LS ;
Swiatlo, E ;
Benton, KA .
VACCINE, 1996, 14 (09) :858-867
[9]  
COWAN MJ, 1978, PEDIATRICS, V62, P721
[10]   PNEUMOCOCCAL SURFACE PROTEIN-A (PSPA) IS SEROLOGICALLY HIGHLY VARIABLE AND IS EXPRESSED BY ALL CLINICALLY IMPORTANT CAPSULAR SEROTYPES OF STREPTOCOCCUS-PNEUMONIAE [J].
CRAIN, MJ ;
WALTMAN, WD ;
TURNER, JS ;
YOTHER, J ;
TALKINGTON, DF ;
MCDANIEL, LS ;
GRAY, BM ;
BRILES, DE .
INFECTION AND IMMUNITY, 1990, 58 (10) :3293-3299